We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Projects granted during 2016 that have a primary purpose of translational applied research - human immune disorders.
Employment Tribunal decision.
The independent advisory group identified which patient groups are at highest risk of serious illness from COVID-19 and would benefit from new COVID-19 treatments.
Use trametinib, authorised either as monotherapy or combined with dabrafenib, with caution in patients with risk factors for gastrointestinal perforation.
Use baricitinib with caution in patients with diverticular disease and in those concomitantly treated with medications associated with an increased risk of diverticulitis.
Use of aliskiren can cause angioedema, a rare and serious side effect, and or acute renal failure.
Patients should use the lowest effective dose, and the shortest duration of treatment necessary to control symptoms.
The Medicines and Medical Devices Bill introduces new safety measures, increases the professions that can prescribe low-risk medicines and allows hospitals to develop personalised medicines.
Projects granted during 2015 that have a primary purpose of multisystemic research.
Confidential reports designed to help you improve the quality of your prescribing and patient safety are now available for practices that contribute to the MHRA’s Clinical Practice Research Datalink.
Healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment.
Update to the independent advisory group report that identifies which patient groups are at highest risk of serious illness from COVID-19 and would benefit from new COVID-19 treatments.
Reminder on risk of serious and fatal toxicity in overdose.
Remind patients to check and remove the mouthpiece cover properly before inhaling a dose and to shake the inhaler to remove loose objects that may have become trapped in the inhaler during storage. The mouthpiece cover shoul…
Prescribing advice should be followed carefully, particularly recommended upper dose limits due to associated higher gastrointestinal risk than most other NSAIDs in the class.
New recommendations after a Europe-wide review of cardiovascular safety.
Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines.
Licensed doses and differences in potency between different inhaled corticosteroids; advice for use with spacer device.
Key MHRA advice and guidance issued so far on medicines safety and pharmacovigilance, including on reporting to the Yellow Card Scheme.
The government has immediately authorised the NHS to use the world’s first coronavirus treatment proven to reduce the risk of death.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).